A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

• Drug: 0.15 mg PF-06649751
  Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
• Drug: 0.5 mg PF-06649751
  Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
• Drug: 0.5 mg PF-06649751
  Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
• Drug: 1.5 mg PF-06649751
  Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
• Drug: 1.5 mg PF-06649751 21 Days
  Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
• Drug: 3.0 mg PF-06649751
  Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
• Drug: 5.0 mg PF-06649751
  Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
• Drug: 8.0 mg PF-06649751
  Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
• Drug: 1.5 mg PF-06649751 in healthy Japanese subjects
  Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.

• Experimental: Cohort 1
  Dosing in healthy Western subjects.
  Intervention: Drug: 0.15 mg PF-06649751
• Experimental: Cohort 2
  Dosing in healthy Western subjects.
  Intervention: Drug: 0.5 mg PF-06649751
• Experimental: Cohort 3
  Dosing in healthy Western subjects.
  Intervention: Drug: 0.5 mg PF-06649751
• Experimental: Cohort 4
  Dosing in healthy Western subjects.
  Intervention: Drug: 1.5 mg PF-06649751
• Experimental: Cohort 5
  Dosing in healthy Western subjects.
  Intervention: Drug: 1.5 mg PF-06649751 21 Days
• Experimental: Cohort 6
  Dosing in healthy Western subjects.
  Intervention: Drug: 3.0 mg PF-06649751
• Experimental: Cohort 7
  Dosing in healthy Western subjects.
  Intervention: Drug: 5.0 mg PF-06649751
• Experimental: Optional Cohort 8
  Dosing in healthy Western subjects. Cohort may not be conducted.
  Intervention: Drug: 8.0 mg PF-06649751
• Experimental: Cohort 9
  Dosing in healthy Japanese subjects.
  Intervention: Drug: 1.5 mg PF-06649751 in healthy Japanese subjects

Inclusion Criteria:

• Healthy males and/or female subjects of non childbearing potential between the ages of 18 and 55 years, inclusive (healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests).
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
• Cohort 9 only: Japanese subjects must have four biologic Japanese grandparents who were born in Japan.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
• Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.